Form 8-K ABBOTT LABORATORIES For: Jan 22
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall St slips as steep oil prices stoke inflation concerns ahead of CPI
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Citi initiates UiPath coverage with Buy rating and $23 target
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- Harry and Meghan surprised by King Charles' letter on their status
- Wall St slips as steep oil prices stoke inflation concerns ahead of CPI
- Qualcomm to issue warrant to Amazon for up to 25M shares
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Abbott Labs (ABT) PT Raised to $140 at BTIG
January 22, 2025 1:54 PM ESTBTIG analyst Marie Thibault raised the price target on Abbott Labs (NYSE: ABT) to $140.00 (from $139.00) while maintaining a Buy rating.
The analyst comments "Abbott reported a Q4 total revenue miss, much of which we attribute to greater Fx headwinds and lower-than-expected COVID testing revenue, and adj. EPS in line with expectations (see our flash note here). In our view, the main message on the call was the positive 2025 outlook, which called for above-consensus organic sales growth, a return to DD adj. EPS growth, and an impressive 150 bps of... More
